|| List of recent Proteins-related patents
| Methods for making fully human bispecific antibodies using a common light chain|
A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline.
Regeneron Pharmaceuticals, Inc.
| Sequence-determined dna fragments encoding acetohydroxyacid synthase proteins|
The present invention provides dna molecules that constitute fragments of the genome of a plant, and polypeptides encoded thereby. The dna molecules are useful for specifying a gene product in cells, either as a promoter or as a protein coding sequence or as an utr or as a 3′ termination sequence, and are also useful in controlling the behavior of a gene in the chromosome, in controlling the expression of a gene or as tools for genetic mapping, recognizing or isolating identical or related dna fragments, or identification of a particular individual organism, or for clustering of a group of organisms with a common trait..
| Preparation of functionalized polypeptides, peptides, and proteins by alkylation of thioether groups|
Reagents are disclosed for chemoselective tagging of methionine residues in peptides and polypeptides, subsequent bioorthogonal tag functionalization, and cleavage of the tags when desired to regenerate unmodified samples. This method compliments other peptide tagging strategies and adds capability for tag removal, which may be useful for release of therapeutic peptides from a carrier, or release of tagged protein digests from solid supports..
The Regents Of The University Of California
| Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules|
The present application discloses compositions and methods of synthesis and use of 18f- or 19f-labeled molecules of use in pet, spect and/or mr imaging. Preferably, the 18f or 19f is conjugated to a targeting molecule by formation of a complex with a group iiia metal and binding of the complex to a bifunctional chelating agent, which may then be directly or indirectly attached to the targeting molecule.
| Compounds and methods for modulating expression apob|
The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index.
Isis Pharmaceuticals, Inc.
| Reverse-turn mimetics and method relating thereto|
Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents.
Choongwae Pharma Corporation
| Methods and compositions for treating viral diseases|
The invention provides a method for treating viral infections and coinfections through the use of inhibitory agents that prevent a unique viral structural protein motifs from binding to host proteins from the clathrin adaptor proteins family and subsequently preventing viral replication.. .
The Board Of Trustees Of The Leland Stanford Junior University
| Compositions and methods for the inhibition of methyltransferases|
Methods and compositions disclosed herein relate to detecting, analyzing, isolating and inhibiting methyltransferases, methyltransferase substrates, s-adenosyl-methionine-binding proteins and rna, including for the treatment of disease.. .
| Use of engrailed proteins for increasing dopamine synthesis by dopaminergic neurons|
The invention relates to the use of an engrailed protein as a medicament for increasing dopamine synthesis by dopaminergic neurons, in particular in the management of conditions associated with a decrease of dopamine levels without loss of dopaminergic neurons. .
Centre National De La Recherche Scientifique
| Reversible pegylated drugs|
Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (fms), to which group a peg moiety is attached. In these pegylated drugs, the peg moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold fmoc or fms structure that is highly sensitive to bases and is removable under physiological conditions.
Yeda Research And Development Co., Ltd.
In vivo transduction with a chimeric aav capsid protein
Recombinant adeno-associated viral (aav) capsid proteins are provided. Methods for generating a library of recombinant adeno-associated viral capsid proteins are also provided..
The Board Of Trustess Of The Leland Stanford Junior University
Phage display using cotranslational translocation of fusion polypeptides
The present invention relates to a filamentous phage display method wherein the polypeptides of interest displayed on the phage particle are cotranslationally translocated across the cytoplasmic membrane of gram-negative bacteria based on the signal recognition particle pathway. This method is particularly suitable for polypeptides, which are known to be difficult to display on phages, and for proteins of cdna libraries and other combinatorial libraries, in particular when derived from very fast folding, stable protein scaffolds.
University Of Zurich
Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Particular embodiments concern homodimers comprising monomers that contain a dimerization and docking domain attached to a precursor.
Ibc Pharmaceuticals, Inc.
Reagents and methods for detecting a polymorphic protein
The present invention provides antibodies that differentially react with allelic variants of a polymorphic protein, methods of identifying same, an antigen binding fragment comprised therein, proteins, cells, viral particles, compositions, and kits comprising same. The invention also provides methods for determining a haptoglobin type of a subject and methods for testing a subject for susceptibility to diabetic complications..
Rappaport Family Institute For Research In The Medical Sciences
Methods for preparing dry formulations of glucose binding protein
Methods and compositions for preparing dry formulations of glucose binding proteins (gbps) are disclosed. The gbps may be stored as a dry formulation without significant loss of activity.
Becton, Dickinson And Company
Detection of glutathionylated proteins
The present invention, in some aspects, relates to systems and methods for determining oxidized proteins, including glutathionylated proteins such as s-glutathionylated proteins. The systems and methods of the invention can be used in vitro (e.g., in cell or tissue culture) or in vivo, for example, to diagnose a person having an oxidative stress condition.
Protective natural gel system
The present invention relates to a protein/peptide composition for protection of surfaces comprising an aqueous solution of at least two components, the first component (a) being a water-soluble protein or a mixture of water-soluble proteins having an average molecular weight mw of at least 30000, and being capable of forming a gel, and the second component (b) being a water-soluble peptide or a mixture of water-soluble peptides mixture having an average molecular weight of 200-10000, and being capable of inhibiting gel formation in said composition. The present invention further relates to a method for preparing such a composition, the use of the composition for protecting a surface, a method for protecting a substrate surface using the composition, and to a substrate surface coated with the composition..
Professor Sigge & Martin Ab
Porcine circovirus type 2 (pcv2) subunit vaccine
Vaccination methods to control pcv2 infection with different pcv2 subtypes are disclosed. Specifically, a pcv2 subtype b (pcv2b) orf2 proteins or immunogenic compositions comprising a pcv2b orf2 protein are used in a method for the treatment or prevention of an infection with pcv2 of a different subtype, the reduction, prevention or treatment of clinical signs caused by an infection with pcv2 of a different subtype, or the prevention or treatment of a disease caused by an infection with pcv2 of a different subtype..
Boehringer Ingelheim Vetmedica, Inc.
Subunit vaccine delivery platform for robust humoral and cellular immune responses
The present invention relates to a probiotic cell transformed with a construct suitable to overexpress and display on the surface of the probiotic cell a fusion protein comprising at least a portion of a transport protein coupled to at least a portion of one or more antigenic proteins or peptides. Probiotic-derived vesicles displaying this fusion protein as well as methods of inducing an immune response using the probiotic cells or vesicles are also disclosed..
Fused antigen vaccines and compositions against streptococcus pneumoniae
Streptococcus pneumoniae is a major health concern, especially in very young, elderly, or immunocompromised patients. The present disclosure provides, inter alia, certain highly effective vaccines and pharmaceutical compositions in streptococcus pneumoniae that contain fusion proteins.
Children's Medical Center Corporation
Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof
This present invention provides c-tab.g5 and c-tab.g5.1 isolated polypeptides comprising the receptor binding domains of c. Difficile toxin a and toxin b as set forth in the amino acid sequences of seq id no: 2 and seq id no: 4.
Valneva Austria Gmbh
Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines
The present invention relates to novel cd4+ and cd8+ t cell epitopes that are specific for hpv-specific e6 and e7 oncoproteins, to peptides comprising these novel t cell epitopes, and to (vaccine) compositions comprising these peptides for use in methods for the prevention and/or treatment of hpv related diseases. Preferred epitopes are recognized by a t cell that infiltrates a cervical neoplastic lesion or by a t cell from a draining lymph node, and are presented by an hla-dq or hla-dp molecule, or an hla-b..
Academisch Ziekenhuis Leiden H.o.d.n. Lumc
Influenza hemagglutinin proteins and methods of use thereof
In some embodiments the present invention provides influenza hemagglutinin (“ha”) polypeptides, proteins, and protein complexes that comprise a stalk domain that is engineered to facilitate maintenance of its native trimeric conformation, even if the head domain of the ha protein is removed or disrupted. In some embodiments, the present invention provides compositions comprising such polypeptides, proteins, and protein complexes, and methods of use of such proteins and compositions, for example as vaccine immunogens..
Recombinant papaya mosaic virus coat proteins and uses thereof in influenza vaccines
Recombinant papaya mosaic virus (papmv) coat proteins comprising one or more antigenic peptides derived from an influenza virus antigen, such as from the m2e peptide, fused at a position within a predicted random coil within 13 amino acids of the n-terminus of the coat protein, uses thereof to prepare virus-like particles (vlps), and uses of the vlps in influenza vaccines.. .
Folia Biotech Inc.
Equine encephalitis virus vaccines and methods of using thereof
Disclosed herein are nucleotide sequences which encode a plurality of structural proteins, except the capsid, of an equine encephalitis virus, wherein the nucleotide sequence is codon-optimized for mammalian expression. The nucleotide sequences are codon-optimized for expression in humans.
Dna sequence, and recombinant preparation of the grass pollen allergen lol p 4
The present invention relates to the provision of a dna sequence of the major grass pollen allergen lol p 4. The invention also encompasses fragments, new combinations of partial sequences and point mutants having a hypoallergenic action.
Merck Patent Gmbh
Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof
The invention provides isolated primate cells preferably human cells that comprise a genetically engineered disruption in a human leukocyte antigen (hla) class ii-related gene, which results in deficiency in mhc class ii expression and function. This invention also provides isolated cells further comprising a genetically engineered disruption in a beta-2 microglobulin (b2m) gene, which results in hla class i/class ii deficiency.
University Of Washington Through Its Center For Commercialization
Methods and compositions for cancer therapy using mutant light molecules with increased affinity to receptors
Methods and compositions are disclosed to target tumor cells with embodiments of the light proteins linked fused or conjugated to a targeting agent. These compositions bind to both human and mouse receptors with affinity sufficient to conduct preclinical and clinical trials, and with increased affinity as compared to the wild type human light protein.
The University Of Chicago
Heparin-binding epidermal growth factor-like growth factor binding proteins
Provided herein are antigen binding proteins, e.g., human and/or monoclonal antibodies that have affinity for heparin-binding epidermal growth factor-like growth factor (hb-egf) and neutralize the biological functions of this growth factor.. .
Multi-specific fab fusion proteins and methods of use
The present disclosure relates generally to multi-specific fab fusion proteins (msfp) which comprise an antibody fab fragment with both n-termini fused to a fusion moiety (fusion moiety a or b). Msfp containing the fab fragment exhibit significantly reduced binding ability of the fab fragment to the fab target.
Anti-tnf/il-17 dual variable domain immunoglobulin and uses thereof
The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.. .
Leukotoxin e/d as a new anti-inflammatory agent and microbicide
The present invention relates to methods for preventing or treating human immunodeficiency virus (hiv) infection, inflammatory conditions, and graft-versus-host-disease (gvhd) in a subject. Therapeutic compositions of the present invention comprise leukocidin e (luke) and/or d proteins or polypeptides.
New York University
The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
The present invention provides a polypeptides comprising a heavy chain domain 2 (hd2) from igm or ige and at least one pharmaceutically active moiety, complexes thereof and their use for therapy and prophylaxis.. .
Universit T Stuttgart
Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
Anti-steap-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-steap-1 antibodies and immunoconjugates thereof are provided.
Compositions and methods for fluorescent genetic bar-coding in mammalian cells for enhanced multiplexing capabilities in flow cytometry
The invention provides cells or populations of cells, including non-human animals or non-human mammals having these cells, where the cells or populations of cells are stably tagged, uniquely identified and genetically barcoded by one or more detectable, e.g., fluorescent, proteins; and methods of making and using them. In alternative embodiments, the invention provides methods for tagging, uniquely identifying or genetically barcoding a cell, a population of cells, or a culture of cells by stably transferring, transfecting, transducing, infecting or implanting one or more nucleic acids encoding readable or detectable, e.g., fluorescent, moieties into the cells.
San Diego State University (sdsu) Foundation, Dba San Diego State University (sdsu) Research Founda
Combinatorial dna library for producing modified n-glycans in lower eukaryotes
The present invention relates to eukaryotic host cells having modified oligosaccharides which may be modified further by heterologous expression of a set of glycosyltransferases, sugar transporters and mannosidases to become host-strains for the production of mammalian, e.g., human therapeutic glycoproteins. The invention provides nucleic acid molecules and combinatorial libraries which can be used to successfully target and express mammalian enzymatic activities such as those involved in glycosylation to intracellular compartments in a eukaryotic host cell.
Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
The present invention relates to conjugates of therapeutically useful anthracyclines with carriers such as polyclonal and monoclonal antibodies, proteins or peptides of natural or synthetic origin; methods for their preparation, pharmaceutical composition containing them and use thereof in treating certain mammalian tumors.. .
Fusion proteins of superfolder green fluorescent protein and use thereof
The present disclosure pertains to methods of producing recombinant peptides that contain between 10 and 200 amino acid residues using novel carrier proteins derived from superfolder green fluorescent protein and its mutants.. .
Suzhou Kunpeng Biotech Co., Ltd.
Cellulose-/chitin-type polymeric light-emitting material
The main object of the present invention is to provide a novel technique using a baf. The invention that achieves the object provides the following: a chimeric protein comprising a luminescent domain and a cellulose- and/or chitin-binding domain, the luminescent domain comprising at least one luminescent protein selected from the group consisting of luciferases and fluorescent proteins..
National Institute Of Advanced Industrial Science And Technology
Composition and inhibition of pkng from mycobacterium tuberculosis
Pkng from mycobacterium tuberculosis is a ser/thr protein kinase that regulates key metabolic processes within the bacterial cell as well as signaling pathways from the infected host cell. This multi-domain protein has a conserved canonical kinase domain with n- and c-terminal flanking regions of unclear functional roles.
Inhibition of mcl-1 and/or bfl-1/a1
This disclosure features compounds and pharmaceutically acceptable salts thereof that inhibit mcl-1 and/or bfl-1/a1 and compositions containing the same. This disclosure also features combinations that include one or more of the mcl-1/bfl-1/a1 inhibitor compounds described herein, or a pharmaceutically acceptable salt thereof; and one or more additional therapeutic agents (e.g., one or more chemotherapeutic agents (including small molecule and/or anti-body based chemotherapy and/or radiation); e.g., one or more therapeutic agents that modulate apoptosis; e.g., one or more therapeutic agents that bind to and inhibit anti-apoptotic proteins or modulate them indirectly; e.g., one or more therapeutic agents that bind to and inhibit, or indirectly modulate, anti-apoptotic bcl-2, bcl-xl, bcl-w, mcl-1, and/or bfl-1/a1; e.g., one or more therapeutic agents that directly bind to and inhibit anti-apoptotic bcl-2/bcl-xl; e.g., agents such as abt-199, abt-263 and abt-737; e.g., abt-737), or (where applicable) a pharmaceutically acceptable salt of the one or more therapeutic agents (as well as compositions containing the same).
Dana-farber Cancer Institute, Inc.
Tyrosine based linkers for the releasable connection of peptides
The invention relates to novel tyrosine based linkers that allow the releasable connection of peptides or proteins with other molecular entities, e.g. Polyethylene glycol, to processes for their preparation and their use for preparing medicaments for the treatment and/or prophylaxis of diseases..
Bayer Intellectual Property Gmbh
Ctla4 proteins and their uses
The present disclosure relates to ctla4 proteins and uses of such proteins, for example to treat diseases associated with the dysregulation of immune responses.. .
Abbvie Biotherapeutics Inc.
Provided herein are peptidomimetic macrocycles containing amino acid sequences with at least two modified amino acids that form an intramolecular cross-link that can help to stabilize a secondary structure of the amino acid sequence. Suitable sequences for stabilization include those with homology to the p53 protein.
Labeling and detection of post translationally modified proteins
Provided in certain embodiments are new methods for forming azido modified biomolecule conjugates of reporter molecules, carrier molecules or solid support. In other embodiments are provided methods for enzymatically labeling a biomolecules with an azide group..
Life Technologies Corporation
Optoelectronic detection system
The invention described herein provides methods for the detection of soluble antigens. In particular, the methods provide for the detection of soluble proteins and chemicals.
Massachusetts Institute Of Technology
Stably tethered structures of defined compositions with multiple functions or binding specificities
The present invention concerns methods and compositions for stably tethered structures of defined compositions with multiple functionalities and/or binding specificities. Particular embodiments concern stably tethered structures comprising a homodimer of a first monomer, comprising a dimerization and docking domain attached to a first precursor, and a second monomer comprising an anchoring domain attached to a second precursor.
Ibc Pharmaceuticals, Inc.
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
The present invention relates to methods for modulating the glycosylation profile of recombinantly-expressed proteins. In particular, the present invention relates to methods of controlling the galactosylation profile of recombinantly-expressed proteins by supplementing production medium, e.g., a hydrolysate-based or a chemically defined medium, with manganese and/or d-galactose..
Method of culturing e. coli cells for high density
Disclosed is a method of culturing e. Coli cells for high density, comprising a cell growth step and an expression induction step by which a maximum of cell mass can be obtained with the concomitant maximum expression of a recombinant protein.
Hanmi Science Co., Ltd.
Method for species-independent measurement of complement activation in animals
A method for species-independent measurement of complement (c) activation in animals. The method comprises taking samples in the range of 3-100 microliter of anticoagulated blood, plasma or serum of an animal (specimen), mixing the specimen with a specificity converting protein matrix (scm), mixing to the specimen/scm mixture an activator of the c system (act), incubating the specimen/scm/act mixture at a temperature between 36° c.
Enzyme concentration and assays
A method of preparing a sample for conducting an assay, the method including: providing an input sample including glycoproteins; capturing glycoproteins from the input sample on a solid support; and washing the sample support to remove unbound portions of the input sample.. .
Advanced Liquid Logic, Inc.
Gelled confection with reduced sugar
A low sugar, low cariogenic, low-laxation gelled confection having acceptable texture, stability, clarity, and flavor delivery, that contains a doctoring agent comprising sucromalt, inulin, brown rice syrup, or combinations thereof; erythritol as the bulking sweetener agent; and a gelling agent comprising gelatin, pectin, starch, dextrin, hydrocolloid, milk proteins, or combinations thereof; wherein the doctoring agent to erythritol ratio is 90:10 to 70:30 wt % solids and the gelled confection has consumer acceptable texture, stability, clarity, and flavor delivery.. .
Wm. Wrigley Jr. Company
Method for making krill meal
A new method for krill meal production has been developed using a two step cooking process. In the first step the proteins and phospholipids are removed from the krill and precipitated as a coagulum.
Aker Biomarine As
Stereoisomer peptides, their polymer conjugates, their encapsulation into nanoparticles, and uses thereof for the treatment of diseases caused by abnormal angiogenesis.
This invention discloses the creation of a novel single ligand-targeted multi-stereoisomer peptide-polymer conjugate compounds comprising a group of different synthetic and chemically modified stereoisomer peptides that have been conjugated to a biocompatible polymer carrying a peptide ligand for targeted delivery and/or encapsulated in ligand targeted polymer nanoparticles. The unique physicochemical properties of the stereoisomer peptides provide therapeutic compounds with ideal biopharmaceutical properties.
Compositions and methods for treating insulin resistance and diabetes mellitus
Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating diabetes and diabetes-associated conditions or disorders (e.g., insulin resistance), or symptoms thereof. Provided are electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents.
Methods of wound care and treatment
Provided are electrokinetically-altered fluids (e.g., gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating a wound to a surface tissue or a symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents.
Implantable liposome embedded matrix composition, uses thereof, and polycaprolactone particles as scaffolds for tissue regeneration
In various embodiments, the present invention describes materials and methods for the local reprogramming of cells in a location where the treatment is applied. The invention can be used to replace lost cells or to restore function to tissue damaged due to disease, injury or genetic defect.
Conjugates of plasmodium falciparum surface proteins as malaria vaccines
Conjugates of ookinete surface protein pfs25 are provided that are efficacious as vaccines against plasmodium falciparum, the most severe form of malaria. Conjugates of ookinete surface protein pvs25 for use as a vaccine against plasmodium vivax are also provided.
The United States Of America As Represented By The Secretary, Department Of Health And Human Service
Disease prevention and alleviation by human myoblast transplantation
Methods and materials are described for human genome prophylaxis and therapy of diseases using myoblast transfer. These methods result in gene transcript changes in multiple pathways.
B-cell receptor complex binding proteins containing t-cell epitopes
The present invention relates to a polypeptide comprising a) a binding peptide binding to at least one protein selected from the group consisting of cd22, cd19, cd20, and cd21, and b) an immunogenic peptide comprising at least one t-cell epitope for use in vaccination of a subject against b-cell hyperproliferation or for use in the modulation of the immune response in a subject. The present invention further relates to a polynucleotide and a vector encoding said polypeptide and a host cell comprising the same.
Oligosaccharides comprising an aminooxy group and conjugates thereof
The invention provides methods for the synthesis of oligosaccharides comprising an aminooxy group. The invention further provides oligosaccharides comprising an aminooxy group, methods for coupling oligosaccharides comprising an aminooxy group to glycoproteins, and oligosaccharide-protein conjugates.
Delivery of packaged rna to mammalian cells
Described herein are compositions relating to alphavirus-based virus-like particles (vlps) and methods for making and using the described vlps. The described compositions include vlps and vectors and cells used to produce the vlps.
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services
Nipah virus envelope pseudotyped lentiviruses and methods of their use
The present invention relates to lentiviral particles which have been pseudotyped with nipah virus (niv) fusion (f) and attachment (g) glycoproteins (nivpp-f/g). Additionally, the present invention relates to truncated niv-f glycoproteins useful in producing such nivpp lentiviral particles, as well as to additional variant peptides which enhance activity.
The Regents Of The University Of California
Treatment of osteoarthritis and pain
The present invention relates to the treatment of osteoarthritis and pain using il-1α and il-1β binding proteins, including anti-il-1α and anti-il-1β antibodies and engineered multivalent and multispecific il-1α and il-1β binding proteins.. .
Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of alzheimer's disease and related tauopathies.
Axon Neuroscience Se